First Psychedelics Training Program Targeting Canadian Mental Health Workers Ends Successfully

ATMA Inc. has partnered with Wayfound and the PAA (a professional body bringing together all psychology professionals within Alberta province in Canada) to conduct the first-ever training program aimed at equipping licensed mental health professionals with the skills that they need to include psychedelic-assisted psychotherapy on the list of services available to patients.

The training program was announced for the first time in February, and available slots quickly filled, leaving other interested professionals to join a long waitlist for the next phase of this training. This huge interest in the course underscores how much the mental health community would like to add more alternatives to the existing ones available to patients.

The training program was designed with input from leading experts in the psychedelics field together with faculty from leading institutions involved in psychedelics research. This training was specifically intended to address one of the most nagging challenges faced by the psychedelics sector: the dire shortage of mental health professionals who are properly trained and understand how psychedelic substances can be integrated into a clinical setting where patients with mental health conditions are treated.

This gap needs to be filled urgently, especially given that the federal government of Canada is increasing access to psychedelic therapies, and there are indications that many of those therapies have a chance of being legalized.

As COVID-19 continues on, the demand for professionals in the mental health field has increased. The training conducted by Wayfound and its partners is a timely program for all professionals yearning for an accredited resource from which they can gain trusted information, knowledge and skills in order to create a convergence between psychedelics and psychology.

Vu-Tran, ATMA’s co-CEO, says that the training program is one step in the organization’s efforts to create infrastructure across the country to make trained professionals available as psychedelic therapy gains increasing acceptance around the country. The added awareness among the professionals will be instrumental in helping policymakers as well as governments make informed decisions with regard to psychedelic-assisted therapies. The learning curve will not be so steep, Vu-Tran adds.

Dr. Angela Grace, one of the professionals who took the course, says the program provided an outstanding overview of psychedelic-assisted therapy and the connections participants made were an invaluable opportunity for them to keep learning and sharing with the best in the field. The accreditation of the training means that the professionals who attend can count it towards meeting their continuing education requirements.

This training is just what is needed in preparation for the therapeutic products that firms such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) may bring onto the market through their different collaborations.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.